Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
AstraZeneca
McKesson
Mallinckrodt
Dow

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR PALIPERIDONE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Paliperidone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00073320 ↗ Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2003-08-01 The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
NCT00074477 ↗ Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 2 2003-10-01 The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00077714 ↗ Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2004-01-01 The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.
NCT00078039 ↗ Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2004-03-01 The primary objective of the double blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in adult patients with schizophrenia.
NCT00083668 ↗ Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2004-04-01 The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Paliperidone

Condition Name

Condition Name for Paliperidone
Intervention Trials
Schizophrenia 147
Schizoaffective Disorder 17
Bipolar Disorder 15
Psychotic Disorders 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Paliperidone
Intervention Trials
Schizophrenia 155
Psychotic Disorders 30
Disease 26
Mental Disorders 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Paliperidone

Trials by Country

Trials by Country for Paliperidone
Location Trials
United States 424
Korea, Republic of 29
Spain 26
China 22
Germany 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Paliperidone
Location Trials
California 38
Texas 32
Florida 26
Illinois 23
Ohio 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Paliperidone

Clinical Trial Phase

Clinical Trial Phase for Paliperidone
Clinical Trial Phase Trials
Phase 4 54
Phase 3 59
Phase 2/Phase 3 1
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Paliperidone
Clinical Trial Phase Trials
Completed 153
Terminated 10
Recruiting 6
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Paliperidone

Sponsor Name

Sponsor Name for Paliperidone
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 57
Janssen Research & Development, LLC 13
Janssen Korea, Ltd., Korea 10
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Paliperidone
Sponsor Trials
Industry 161
Other 76
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKinsey
Colorcon
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.